Hospital
Taos Health Systems, INC., Holy Cross Hospital
Taos Health Systems, INC., Holy Cross Hospital was paid $30.90M by Medicaid between Jan 2018 and Dec 2024, across 235 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoTAOS HEALTH SYSTEMS, INC., HOLY CROSS HOSPITAL
TAOS, NM 87571
TAOS, NM 87571
33aNPI1902338049assigned 03/29/2017
33bProvider typeCritical Access Hospital
28Total paid$30.90M
24GClaims497,231
24DCodes billed235
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in New Mexico
Rank by total paid#2 of 6
Median peer was paid$15.48M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,890 | $5.82M | |
| 2019 | 58,025 | $4.00M | |
| 2020 | 46,399 | $3.23M | |
| 2021 | 62,822 | $3.36M | |
| 2022 | 71,357 | $4.03M | |
| 2023 | 85,615 | $5.06M | |
| 2024incomplete | 81,123 | $5.41M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 34,888 | 30,861 | $7.22M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 14,627 | 13,390 | $3.75M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 21,527 | 19,326 | $3.13M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 2,953 | 2,775 | $1.36M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 3,611 | 3,359 | $1.08M |
| G0378 | Hospital observation service, per hour | 2.7% | 843 | 762 | $833K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 9,238 | 8,258 | $693K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 5,706 | 4,820 | $644K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 8,454 | 7,198 | $538K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,764 | 3,608 | $510K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 9,256 | 8,769 | $482K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 5,907 | 3,981 | $440K |
223 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 7,944 | $381K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 5,720 | $376K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 1,140 | $367K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 8,661 | $355K |
| 80053 | Comprehensive metabolic panel | 1.1% | 26,595 | $328K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 4,010 | $318K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,891 | $296K |
| 97597 | <1% | 5,273 | $293K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,558 | $284K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,570 | $279K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,244 | $264K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,340 | $263K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 782 | $249K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,016 | $247K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,400 | $225K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,195 | $222K |
| 36415 | Collection of venous blood by venipuncture | <1% | 42,411 | $210K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,123 | $196K |
| 84484 | <1% | 5,699 | $166K | |
| 73564 | <1% | 1,152 | $153K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 354 | $149K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,580 | $145K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,314 | $140K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,324 | $139K |
| 73610 | <1% | 915 | $118K | |
| 0002A | <1% | 2,063 | $111K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 299 | $109K |
| 76830 | Ultrasound, transvaginal | <1% | 730 | $104K |
| 73030 | <1% | 847 | $103K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 198 | $98K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,300 | $97K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 160 | $96K |
| 0001A | <1% | 2,107 | $95K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 728 | $86K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 215 | $85K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 902 | $83K |
| 81001 | <1% | 9,185 | $81K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 559 | $80K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,759 | $79K |
| 80061 | Lipid panel | <1% | 5,534 | $78K |
| 87800 | <1% | 1,596 | $77K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 760 | $76K |
| 70486 | <1% | 259 | $76K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,438 | $75K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,185 | $74K |
| 83690 | <1% | 6,639 | $71K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 441 | $65K |
| 73630 | <1% | 765 | $65K | |
| 80306 | <1% | 1,366 | $62K | |
| 83880 | <1% | 2,702 | $59K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 9,636 | $58K |
| 73130 | <1% | 620 | $57K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,199 | $57K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,107 | $52K |
| 83605 | <1% | 2,573 | $47K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 305 | $47K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,329 | $46K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,363 | $46K |
| 73110 | <1% | 521 | $45K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,674 | $45K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 307 | $43K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 678 | $42K |
| 85610 | <1% | 7,414 | $41K | |
| 84439 | <1% | 2,167 | $35K | |
| 96367 | <1% | 874 | $35K | |
| 81025 | <1% | 2,500 | $35K | |
| 87040 | <1% | 1,943 | $35K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 78 | $35K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 835 | $31K |
| 84703 | <1% | 1,961 | $31K | |
| 83735 | <1% | 3,779 | $28K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 685 | $27K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 110 | $27K |
| 87077 | <1% | 2,341 | $26K | |
| 87186 | <1% | 2,388 | $25K | |
| 81003 | <1% | 3,975 | $24K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,132 | $24K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 830 | $24K |
| 86140 | <1% | 2,515 | $23K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,146 | $23K |
| 86803 | <1% | 1,486 | $22K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 33 | $21K |
| 73502 | <1% | 285 | $21K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,905 | $20K |
| 80076 | <1% | 1,971 | $20K | |
| 74018 | <1% | 232 | $20K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 198 | $20K |
| 93971 | <1% | 145 | $19K | |
| 96376 | <1% | 2,738 | $19K | |
| 0003A | <1% | 307 | $18K | |
| 97162 | <1% | 273 | $17K | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 824 | $17K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 38 | $16K |
| 86850 | <1% | 1,020 | $16K | |
| 82728 | <1% | 1,046 | $15K | |
| 86900 | <1% | 1,101 | $15K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 650 | $14K |
| 85730 | <1% | 2,222 | $14K | |
| 73140 | <1% | 153 | $14K | |
| 85379 | <1% | 1,228 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,555 | $13K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,155 | $13K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 752 | $13K |
| 72100 | <1% | 111 | $13K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 263 | $12K |
| 73221 | <1% | 26 | $12K | |
| 72110 | <1% | 88 | $12K | |
| 88142 | <1% | 507 | $11K | |
| 87070 | <1% | 1,044 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,488 | $11K |
| 80055 | <1% | 123 | $11K | |
| 97161 | <1% | 295 | $11K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 128 | $11K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 152 | $11K |
| 71250 | <1% | 40 | $10K | |
| 90715 | <1% | 673 | $10K | |
| D1120 | Dental cleaning, child | <1% | 39 | $10K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,020 | $9K |
| 76801 | <1% | 60 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,762 | $9K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 812 | $9K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,347 | $9K |
| 86901 | <1% | 1,180 | $9K | |
| 93017 | <1% | 33 | $9K | |
| 83550 | <1% | 1,026 | $9K | |
| 84702 | <1% | 309 | $8K | |
| 85652 | <1% | 2,142 | $8K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $8K |
| 82043 | <1% | 799 | $8K | |
| 12001 | <1% | 54 | $7K | |
| 85027 | <1% | 1,009 | $7K | |
| 76536 | <1% | 50 | $7K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 893 | $7K |
| 82607 | <1% | 474 | $7K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 55 | $7K |
| 83540 | <1% | 1,098 | $7K | |
| 59025 | Fetal non-stress test | <1% | 41 | $7K |
| 87653 | <1% | 115 | $7K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 296 | $6K |
| 82570 | <1% | 1,213 | $6K | |
| 72072 | <1% | 42 | $6K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 24 | $6K |
| 73080 | <1% | 71 | $6K | |
| J3490 | Unclassified drugs | <1% | 822 | $6K |
| 73590 | <1% | 66 | $6K | |
| 80074 | <1% | 64 | $5K | |
| 97803 | <1% | 204 | $5K | |
| 85007 | <1% | 738 | $5K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 25 | $5K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 586 | $5K |
| 0064A | <1% | 60 | $5K | |
| 82140 | <1% | 332 | $5K | |
| 73560 | <1% | 55 | $4K | |
| 86592 | <1% | 491 | $4K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 27 | $4K |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 15 | $4K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 12 | $4K |
| 51702 | <1% | 39 | $3K | |
| 82803 | <1% | 111 | $3K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 12 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 78 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $3K |
| 99223 | Prolong inpt eval add15 m | <1% | 18 | $3K |
| D1206 | Topical application of fluoride varnish | <1% | 12 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 866 | $2K |
| 82746 | <1% | 166 | $2K | |
| 82947 | <1% | 298 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 685 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 74 | $2K |
| 87081 | <1% | 125 | $2K | |
| 86038 | <1% | 100 | $1K | |
| 0031A | <1% | 25 | $1K | |
| 87634 | <1% | 15 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 18 | $1K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 12 | $1K |
| 87581 | <1% | 15 | $1K | |
| 76857 | <1% | 12 | $1K | |
| 73552 | <1% | 13 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 25 | $879.58 |
| 87075 | <1% | 83 | $877.50 | |
| 73090 | <1% | 12 | $819.25 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 76 | $818.72 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 285 | $807.77 |
| H0049 | Alcohol and/or drug screening | <1% | 177 | $802.90 |
| 84481 | <1% | 38 | $778.07 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 54 | $754.42 |
| 84100 | <1% | 153 | $657.60 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 13 | $549.56 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 215 | $548.54 |
| 80069 | <1% | 12 | $526.92 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 129 | $503.92 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 242 | $491.25 |
| 86141 | <1% | 51 | $483.69 | |
| 93016 | <1% | 33 | $390.35 | |
| 85014 | <1% | 85 | $357.48 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 177 | $325.51 |
| 82550 | <1% | 45 | $323.39 | |
| 87205 | <1% | 49 | $308.11 | |
| 87088 | <1% | 22 | $298.38 | |
| A9270 | Non-covered item or service | <1% | 513 | $287.88 |
| 93018 | <1% | 33 | $256.73 | |
| 85018 | <1% | 65 | $248.13 | |
| 83525 | <1% | 12 | $240.40 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 13 | $228.13 |
| 82272 | <1% | 43 | $222.50 | |
| 82950 | <1% | 39 | $221.05 | |
| 87340 | <1% | 13 | $201.98 | |
| 82962 | <1% | 23 | $198.78 | |
| 82784 | <1% | 13 | $184.20 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 17 | $176.53 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 26 | $162.18 |
| 84156 | <1% | 49 | $150.82 | |
| 86308 | <1% | 12 | $106.60 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 15 | $97.13 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 40 | $86.28 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 26 | $84.35 |
| 83615 | <1% | 12 | $53.38 | |
| 84550 | <1% | 12 | $34.60 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 16 | $30.35 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 12 | $25.92 |
| 91300 | <1% | 1,069 | $5.61 | |
| 80050 | General health panel | 0% | 21 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROZENBOOM, STEVEN (CFO)